Clinical analysis of combination chemotherapy for advanced and recurrent gastric cancer with 5-fluorouracil (5-FU) and cis-diamminedichloroplatinum (CDDP)

Combination chemotherapy with 5-fluorouracil (5-FU) and cis-diamminedichloroplatinum (CDDP) was given to 16 patients in advanced and recurrent gastric cancer. The regimen consisted of 5-FU 1000 mg/m(2) (day 1-5, continuous infusion) and CDDP 100 mg/m(2) (day 3, 1 hr. drip infusion). The interval was from the 6th day to the 21st day. Sixteen patients were evaluated. In the treated cases, ten patients were regarded as partial response (PR) and six as no change (NC). Overall response rate was 62.5% (10/16). Three of the sixteen patients were now surviving. The longest survival period was 17.3 months. The average survival period was 8.61 months. Adverse reactions were severe leukocytopenia, thrombocytopenia, mild stomatitis, nausea, vomiting. alopecia. renal dysfunction and peripheral neuropathy. This therapy is thought to be effective against advanced and recurrent gastric cancer.